Astria Therapeutics (NASDAQ:ATXS) PT Lowered to $16.00

Astria Therapeutics (NASDAQ:ATXS) had its price objective decreased by HC Wainwright from $18.00 to $16.00 in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently commented on ATXS. Wedbush reaffirmed an outperform rating and issued a $17.00 target price on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Jefferies Financial Group raised their target price on Astria Therapeutics from $22.00 to $27.00 and gave the stock a buy rating in a research report on Monday, March 25th.

Astria Therapeutics Stock Down 1.6 %

ATXS opened at $9.64 on Tuesday. The firm has a market cap of $529.24 million, a PE ratio of -4.12 and a beta of 0.69. The business has a fifty day simple moving average of $13.31 and a 200-day simple moving average of $9.27. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, equities research analysts anticipate that Astria Therapeutics will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Christopher Morabito sold 9,200 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Christopher Morabito sold 9,200 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Perceptive Advisors Llc acquired 2,481,350 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were purchased at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the acquisition, the director now owns 4,873,721 shares of the company’s stock, valued at approximately $58,923,286.89. The disclosure for this purchase can be found here. 3.40% of the stock is owned by corporate insiders.

Institutional Trading of Astria Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ATXS. AJOVista LLC purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth $51,000. Jump Financial LLC purchased a new stake in shares of Astria Therapeutics during the third quarter worth $111,000. Panagora Asset Management Inc. bought a new position in Astria Therapeutics during the fourth quarter valued at about $119,000. Trexquant Investment LP bought a new position in Astria Therapeutics during the fourth quarter valued at about $409,000. Finally, ADAR1 Capital Management LLC bought a new position in Astria Therapeutics during the fourth quarter valued at about $1,469,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.